Clinical Trial Update: Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for an oral EGFR inhibitor YK-209A in advanced non-small cell lung cancer (Phase 1/Phase 2) with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• YK-209A (YK-209A)

Snippet

Sponsor: Suzhou Puhe Pharmaceutical Technology Co., LTD | Conditions: Treatment, Treatment Side Effects | Phase 1, Phase 2 | Status: UNKNOWN